Sign Out
Pharmacology:Pharmacodynamics: Beclomethasone inhibits the adherence of neutrophils and monocyte-macrophages to the capillary endothelial cells of the inflamed area. It blocks the effect of macrophage migration inhibitory factor. Beclomethasone also decreases the activation of plasminogen to plasmin and by inhibition of phospholipase A2 activity it reduces the formation of prostaglandins and leucotrienes in the local tissue.
Pharmacokinetics: Beclomethasone Dipropionate (BDP) given intranasally (200 μg) to volunteers was not detectable in plasma or urine. It is transformed slowly and incompletely to 17-Beclomathasone monopropionate (17-BMP) when incubated with bronchial secretions in vitro. When incubated with human lung tissue, BDP is rapidly hydrolyzed (half-life of 10 min.) in the presence of lysosomal esterases to 17-BMP, which has a half-life of 12 h. 17-BMP is very stable in lung tissue with only 10% being converted to beclomethasone after 2 h.
